Stock listing

OTC:METXF ME Therapeutics Holdings, Inc. Stock

US listing (OTC) of ME Therapeutics Holdings, Inc. · home listing CSE:METX

Follow ME Therapeutics Holdings, Inc. into a list and get an email when it puts out news.

Home listing price · CSE:METX

$1.05 CAD 0.00 (0.0%)

Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:METX

Past year -73.8% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$1.05 – $1.05 CADNov 19, 2026
Market cap
$31.91M CADAt the close on Nov 19, 2026 · price × 30.39M shares outstanding
52-week range
$0.79 – $4.10 CADLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$2,554 CADMedian day 0 shares · 38 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
ME Therapeutics Holdings, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
CSE:METX · Home$1.05 CAD0.00 (0.0%)—$1.05$1.05$1.05$1.05Close on Nov 19, 2026
Frankfurt:Q9T€0.752 EUR+0.006 (+0.8%)—€0.752€0.752€0.752€0.746Close on Nov 17, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · CSE:METX · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.05+0.05+5.0%$1.05$1.05$1.0538,000
$1.00-0.05-4.8%$0.95$1.00$0.9541,550
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.051,000
$1.05-0.05-4.5%$1.10$1.10$1.0510,628
$1.100.000.0%$1.10$1.10$1.100
$1.100.000.0%$1.10$1.10$1.100
$1.100.000.0%$1.10$1.10$1.100
$1.10+0.04+3.8%$1.10$1.10$1.10200
$1.060.000.0%$1.06$1.06$1.060
$1.060.000.0%$1.06$1.06$1.060
$1.060.000.0%$1.06$1.06$1.060
$1.060.000.0%$1.06$1.06$1.060
$1.060.000.0%$1.06$1.06$1.060
$1.06+0.01+1.0%$1.06$1.06$1.06100
$1.05+0.10+10.5%$1.05$1.05$1.05600
$0.95-0.85-47.2%$0.96$0.96$0.952,500
$1.800.000.0%$1.80$1.80$1.800
$1.80+0.20+12.5%$1.80$1.80$1.80200
$1.60-1.20-42.9%$1.60$1.61$1.514,020
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.80+0.80+40.0%$2.80$2.80$2.80500
$2.00-0.80-28.6%$1.75$2.00$1.601,300
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.800.000.0%$2.80$2.80$2.800
$2.80+0.80+40.0%$2.80$2.80$2.80300
$2.000.000.0%$2.00$2.00$2.000
$2.00+0.25+14.3%$1.85$2.00$1.85200
$1.750.000.0%$1.75$1.75$1.750
$1.750.000.0%$1.76$1.76$1.753,008
$1.75-2.35-57.3%$2.80$2.80$1.752,200
$4.100.000.0%$4.10$4.10$4.100
$4.10+1.10+36.7%$3.73$4.10$3.733,276
$3.00+1.40+87.5%$1.60$3.00$1.602,900
$1.60-0.65-28.9%$1.60$1.60$1.601,100
$2.250.000.0%$2.25$2.25$2.250
$2.250.000.0%$2.25$2.25$2.250
$2.25-0.25-10.0%$2.25$2.25$2.251,200
$2.500.000.0%$2.50$2.50$2.500
$2.500.000.0%$2.50$2.50$2.500
$2.500.000.0%$2.50$2.50$2.500
$2.500.000.0%$2.50$2.50$2.500
$2.500.000.0%$2.50$2.50$2.50900
$2.50+0.35+16.3%$2.50$2.50$2.50101
$2.15+0.65+43.3%$2.00$2.15$2.00475
$1.50-0.40-21.1%$1.50$1.50$1.509,400
$1.900.000.0%$1.90$1.90$1.900
$1.900.000.0%$1.90$1.90$1.900
$1.90-0.90-32.1%$3.04$3.25$1.901,500
$2.800.000.0%$2.80$2.80$2.800
$2.80+1.04+59.1%$2.80$2.80$2.80100
$1.76+0.01+0.6%$1.76$1.76$1.76300
Ticker
OTC:METXF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All ME Therapeutics Holdings, Inc. news

ME Therapeutics Holdings, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
9 in the last 12 months · 28 in all · newest Nov 9, 2026 · oldest 2023
Decks
4 decks · latest June 2026

Where ME Therapeutics Holdings, Inc. is listed

ListingExchangeCountryCurrency
CSE:METX · Home listingCSECanadaCAD
Cboe Canada:METXCboe CanadaCanadaCAD
OTC:METXF · This pageOTCUnited StatesUSD
Frankfurt:Q9TFrankfurtGermanyEUR

Valuation

Price/book 49.5× against a median of 1.1×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Mar 31, 2026 · price Nov 19, 2026

Enterprise value
$31.37M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
49.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P/TSX Composite
0.52

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ME Therapeutics Holdings, Inc. · CSE:METXUS$22.25MUS$21.88Mn/an/an/a49.5×n/a0.0×0.52
Incannex Healthcare Inc. · NASDAQ:IXHLUS$23.33M−US$44.85Mn/an/an/a0.3×n/a0.0×0.98
Actinogen Medical Limited · ASX:ACWUS$23.08MUS$15.17Mn/an/an/a1.6×n/a0.2×n/a
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
CervoMed Inc. · NASDAQ:CRVOUS$22.09MUS$2.49Mn/a285×n/a1.3×n/a0.0×1.97
Sona Nanotech, Inc. · CSE:SONAUS$21.84MUS$22.06Mn/an/an/an/an/an/a0.47
Mendus AB · OMXSTO:IMMUUS$21.76MUS$17.65Mn/an/an/a0.4×n/a0.0×n/a
Metagenomi Therapeutics, Inc. · NASDAQ:MGXUS$21.36M−US$44.10Mn/a−6.2×n/a0.2×n/a0.4×1.65
NanoGroup SA · GPW:NNGUS$21.32MUS$18.78Mn/an/an/a4.0×n/a0.0×n/a
Cel-Sci Corporation · AMEX:CVMUS$21.28MUS$14.76Mn/an/an/a1.9×n/a0.0×1.13
Median of the othersUS$21.96MUS$14.96M140×1.1×0.0×0.98

Team and board

Officers

OfficerRole
Salim DhanjiChief Executive Officer & Founder
Quinn MartinChief Financial Officer

Board

DirectorRole
John PriatelDirector
Karim NanjiDirector
Kenneth HarderDirector

Decks

DeckKindSlidesDate
Investor Presentation (June 2026)Investor deck19 slidesJune 2026
Investor Presentation (October 2025)Investor deck16 slidesOct 16, 2025
Investor Presentation (March 2025)Investor deck24 slidesMarch 2025
Investor Presentation (December 2023)Investor deck25 slidesDecember 2023

Open Decks

Financings

RaiseDateIn US dollars
Private placement of units
Closed: C$576,501 raised · C$1.7 a unit · Warrants at C$2 for 36 months
Buyers: John Priatel (294,118 Units for an investment of $500,000.60)
Insiders: Director John Priatel was issued 294,118 Units for an investment of $500,000.60; related party transaction under MI 61-101
Use of proceeds: R&D, evaluating strategic transactions, pursuing a U.S. listing, marketing, investor relations, working capital and general corporate purposes
Jul 17, 2026US$411,375

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CAD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Research and development412.1K312.0K27.1K54.7K
Selling, general and administrative780.1K1.06M950.2K97.3K
Operating income-1.22M-1.37M-6.55M-162.8K
Depreciation and amortization83.3K405060
EBITDA-1.13M-1.37M-6.55M-162.7K
Interest expense12.7K07.46K10.8K
Income before tax-1.19M-1.29M-6.52M-145.8K
Net income-1.19M-1.29M-6.52M-145.8K
Earnings per share, basic-0.04-0.05-0.28-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents1.35M1.50M647.1K77.4K
Short-term investments57.5K0
Current assets1.50M1.54M671.7K102.2K
Property, plant and equipment160200250
Total assets1.76M1.54M671.9K102.5K
Accounts payable155.2K46.1K106.7K34.2K
Current liabilities245.4K62.9K148.5K173.9K
Long-term debt060.0K
Total liabilities256.3K62.9K148.5K233.9K
Shareholders' equity1.50M1.48M523.4K-131.5K
Shares outstanding29.6M25.2M23.6M23.6M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-862.3K-657.9K-303.2K-135.7K
Capital spending-216.2K000
Free cash flow-1.08M-657.9K-303.2K-135.7K
Cash from investing0757.4K
Cash from financing995.5K1.51M115.5K140.0K
Share buybacks1.55M0
Change in cash-151.3K849.6K569.8K4.32K

Open Financials

Cap table

Built by 6ix from ME Therapeutics Holdings, Inc.’s releases · as of Jul 17, 2026

Common shares
30,388,612
Fully diluted
32,438,612

Fully diluted

LineSharesAs of
Common shares30,388,612Jul 17, 2026
Options and RSUs2,050,000

Warrants and options

Lot
Warrants · C$2.00 · expire about Jul 2029
Stock options · C$1.05 · expire Nov 5, 2028
Stock options · C$1.99 · expiry not stated

Share count over time

CountShares
Jul 17, 202630,388,612
Mar 31, 202630,049,494

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Rahim Dhanji
10% Security Holder of Issuer
Sale200,000CAD 0.70CAD 140KNov 4, 2026
Rahim Dhanji
10% Security Holder of Issuer
Buy100CAD 2.00CAD 200Oct 7, 2026
John Jacob Priatel
10% Security Holder of Issuer
Buy294,118CAD 1.70CAD 500KJul 16, 2026
Rahim Dhanji
10% Security Holder of Issuer
Buy200CAD 1.99CAD 398Jun 29, 2026
Jamil Kassam
Senior Officer of Issuer
Buy200CAD 2.50CAD 500Feb 18, 2026
Jamil Kassam
Senior Officer of Issuer
Buy200CAD 2.50CAD 500Feb 10, 2026
Jamil Kassam
Senior Officer of Issuer
Buy100CAD 3.48CAD 348Feb 6, 2026
Jamil Kassam
Senior Officer of Issuer
Buy100CAD 3.74CAD 374Feb 6, 2026
Jamil Kassam
Senior Officer of Issuer
Buy100CAD 3.48CAD 348Feb 6, 2026
Jamil Kassam
Senior Officer of Issuer
Buy100CAD 3.75CAD 375Feb 4, 2026
All 13 trades
TradeTradeSharesPriceValueDate
Jamil Kassam
Senior Officer of Issuer
Buy500CAD 3.50CAD 1,750Feb 3, 2026
Jamil Kassam
Senior Officer of Issuer
Buy500CAD 3.49CAD 1,745Feb 2, 2026
Jamil Kassam
Senior Officer of Issuer
Buy300CAD 3.50CAD 1,050Feb 2, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John PriatelDirector · Since at least Jul 17, 2026
Karim NanjiDirector · Since at least Nov 5, 2026
Kenneth HarderDirector · Since at least Nov 5, 2026
Quinn MartinChief Financial Officer · Since at least Nov 5, 2026
Salim DhanjiChief Executive Officer & Founder · Since at least Mar 3, 2025

Open People

Log in to ask 6ix AI your own questions about ME Therapeutics Holdings, Inc.